One To Watch

Nkarta

A biotechnology company developing CAR natural killer (NK) cell therapies for autoimmune diseases and cancer using gene-edited allogeneic platforms.

Company Overview

A biotechnology company developing CAR natural killer (NK) cell therapies for autoimmune diseases and cancer using gene-edited allogeneic platforms. Nkarta focuses on engineered NK cells designed to safely eliminate disease-causing B cells while maintaining improved safety profiles compared to traditional CAR-T approaches. The company aims to bring transformative cell therapy to autoimmune patients, building on the proven success of CAR-T therapies in oncology.

Headquarters and Global Presence

Nkarta is headquartered in South San Francisco, California. The company operates as a US-focused biotechnology enterprise with approximately 152 employees. Its operations are primarily concentrated in the Bay Area biotech hub.

Founding and History

Founded in the mid-2010s as a private biotechnology venture by former academics, clinicians, and seasoned biopharmaceutical executives. The company went public on Nasdaq under the ticker NKTX. Nkarta has raised $114 million in funding, with Samsara BioCapital among its investors.

Therapy Areas and Focus

Nkarta targets autoimmune diseases including systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis, alongside cancer applications. The company's strategy builds on breakthrough CAR-T studies showing drug-free remissions in lupus nephritis patients. Nkarta's approach addresses unmet needs in autoimmune disorders where B cell depletion could provide transformative benefits.

Technology Platforms and Modalities

The company's platform centers on CAR natural killer cells engineered with CRISPR gene editing technology. Nkarta's CAR NK cells are designed to be administered at immediately active therapeutic doses without requiring proliferation inside patients' bodies. This approach aims to deliver enhanced safety compared to CAR-T therapies while maintaining potent anti-B cell activity.

Key Pipeline and Programs

NKX019, the company's lead ADAM17 knockout CD19 CAR-NK therapy, is advancing through Phase I development. The multicenter Ntrust-2 trial is currently enrolling patients with systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis. Nkarta's pipeline spans both autoimmune and oncology applications, with additional early-stage programs utilizing its gene-edited NK cell platform.

Key Personnel

Paul Hastings serves as Chief Executive Officer and board member, leading the company's strategic direction. Shawn Rose holds the position of Chief Medical Officer and Head of Research and Development. Bridgette Housley serves as Vice President, General Counsel and Secretary.

Strategic Partnerships

Nkarta has established a global collaboration with CRISPR Therapeutics to develop gene-edited cell therapies for cancer. This partnership provides access to world-class gene editing capabilities across Nkarta's preclinical pipeline. CRISPR's expertise in CD70 biology and allogeneic T cell development aims to accelerate early-stage Nkarta programs.

FAQ Section

Successfully translating CAR-NK cell therapy from cancer to autoimmune diseases while demonstrating superior safety and efficacy. The company must prove its approach can match CAR-T efficacy in B cell depletion without the associated toxicities.

NK cells offer inherent advantages over T cells including reduced risk of graft-versus-host disease and cytokine release syndrome. They can be used as off-the-shelf allogeneic products, potentially enabling broader patient access and reduced manufacturing complexity.

Nkarta combines CAR-NK technology with CRISPR gene editing to create immediately active cells that don't require in-vivo proliferation. The focus on autoimmune applications differentiates it from the predominantly cancer-focused CAR-T field.

NKX019 represents the first major test of CAR-NK therapy in autoimmune diseases, targeting CD19-positive B cells in conditions with significant unmet need. Success could validate an entirely new therapeutic class for autoimmune disorders.

Autoimmune diseases including systemic sclerosis, inflammatory myopathy, and vasculitis form the primary focus. The company also maintains oncology programs, leveraging the broader applicability of its CAR-NK platform.

Clinical-stage company with NKX019 in Phase I trials through the Ntrust-2 study. The company maintains multiple preclinical programs and continues platform development through its CRISPR collaboration.

Key catalysts and risks to monitor include:

• Ntrust-2 Phase I safety and efficacy data readouts

• Manufacturing scalability and cost-effectiveness demonstrations

• CRISPR collaboration milestone achievements and pipeline expansion

• Competition from established CAR-T companies entering autoimmune space

Want to Update your Company's Profile?